Clinical • Enrollment closed • Enrollment change • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
|
CCND1 overexpression
|
Imbruvica (ibrutinib) • BNC105